Cogent Biosciences (COGT) EBT: 2017-2020
Historic EBT for Cogent Biosciences (COGT) over the last 4 years, with Dec 2020 value amounting to -$11.4 million.
- Cogent Biosciences' EBT fell 594.78% to -$11.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$82.1 million, marking a year-over-year decrease of 157.14%. This contributed to the annual value of -$82.1 million for FY2020, which is 157.14% down from last year.
- Per Cogent Biosciences' latest filing, its EBT stood at -$11.4 million for Q4 2020, which was up 80.09% from -$57.2 million recorded in Q3 2020.
- In the past 5 years, Cogent Biosciences' EBT ranged from a high of $2.3 million in Q4 2019 and a low of -$57.2 million during Q3 2020.
- Its 3-year average for EBT is -$12.4 million, with a median of -$9.7 million in 2018.
- Its EBT has fluctuated over the past 5 years, first surged by 126.77% in 2019, then tumbled by 594.78% in 2020.
- Quarterly analysis of 4 years shows Cogent Biosciences' EBT stood at -$6.8 million in 2017, then dropped by 26.77% to -$8.6 million in 2018, then spiked by 126.77% to $2.3 million in 2019, then slumped by 594.78% to -$11.4 million in 2020.
- Its EBT was -$11.4 million in Q4 2020, compared to -$57.2 million in Q3 2020 and -$7.4 million in Q2 2020.